178 related articles for article (PubMed ID: 36425562)
1. Systematic assessment and optimizing algorithm of tumor mutational burden calculation and their implications in clinical decision-making.
Sun D; Xu M; Pan C; Tang H; Wang P; Wu D; Luo H
Front Oncol; 2022; 12():972972. PubMed ID: 36425562
[TBL] [Abstract][Full Text] [Related]
2. Tumor mutational burden assessment and standardized bioinformatics approach using custom NGS panels in clinical routine.
Dupain C; Gutman T; Girard E; Kamoun C; Marret G; Castel-Ajgal Z; Sablin MP; Neuzillet C; Borcoman E; Hescot S; Callens C; Trabelsi-Grati O; Melaabi S; Vibert R; Antonio S; Franck C; Galut M; Guillou I; Halladjian M; Allory Y; Cyrta J; Romejon J; Frouin E; Stoppa-Lyonnet D; Wong J; Le Tourneau C; Bièche I; Servant N; Kamal M; Masliah-Planchon J
BMC Biol; 2024 Feb; 22(1):43. PubMed ID: 38378561
[TBL] [Abstract][Full Text] [Related]
3. Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel.
Wang Z; Duan J; Cai S; Han M; Dong H; Zhao J; Zhu B; Wang S; Zhuo M; Sun J; Wang Q; Bai H; Han J; Tian Y; Lu J; Xu T; Zhao X; Wang G; Cao X; Li F; Wang D; Chen Y; Bai Y; Zhao J; Zhao Z; Zhang Y; Xiong L; He J; Gao S; Wang J
JAMA Oncol; 2019 May; 5(5):696-702. PubMed ID: 30816954
[TBL] [Abstract][Full Text] [Related]
4. Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project.
Merino DM; McShane LM; Fabrizio D; Funari V; Chen SJ; White JR; Wenz P; Baden J; Barrett JC; Chaudhary R; Chen L; Chen WS; Cheng JH; Cyanam D; Dickey JS; Gupta V; Hellmann M; Helman E; Li Y; Maas J; Papin A; Patidar R; Quinn KJ; Rizvi N; Tae H; Ward C; Xie M; Zehir A; Zhao C; Dietel M; Stenzinger A; Stewart M; Allen J;
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32217756
[TBL] [Abstract][Full Text] [Related]
5. Assessment of Tumor Mutational Burden in Pediatric Tumors by Real-Life Whole-Exome Sequencing and In Silico Simulation of Targeted Gene Panels: How the Choice of Method Could Affect the Clinical Decision?
Noskova H; Kyr M; Pal K; Merta T; Mudry P; Polaskova K; Ivkovic TC; Adamcova S; Hornakova T; Jezova M; Kren L; Sterba J; Slaby O
Cancers (Basel); 2020 Jan; 12(1):. PubMed ID: 31963488
[TBL] [Abstract][Full Text] [Related]
6. Interplay between Tumor Mutational Burden and Mutational Profile and Its Effect on Overall Survival: A Pilot Study of Metastatic Patients Treated with Immune Checkpoint Inhibitors.
Xavier CB; Lopes CDH; Awni BM; Campos EF; Alves JPB; Camargo AA; Guardia GDA; Galante PAF; Jardim DL
Cancers (Basel); 2022 Nov; 14(21):. PubMed ID: 36358851
[TBL] [Abstract][Full Text] [Related]
7. Universal cutoff for tumor mutational burden in predicting the efficacy of anti-PD-(L)1 therapy for advanced cancers.
Mo SF; Cai ZZ; Kuai WH; Li X; Chen YT
Front Cell Dev Biol; 2023; 11():1209243. PubMed ID: 37305681
[No Abstract] [Full Text] [Related]
8. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
Alborelli I; Leonards K; Rothschild SI; Leuenberger LP; Savic Prince S; Mertz KD; Poechtrager S; Buess M; Zippelius A; Läubli H; Haegele J; Tolnay M; Bubendorf L; Quagliata L; Jermann P
J Pathol; 2020 Jan; 250(1):19-29. PubMed ID: 31471895
[TBL] [Abstract][Full Text] [Related]
9. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.
Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y
BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687
[TBL] [Abstract][Full Text] [Related]
10. Tumor mutation burden for predicting immune checkpoint blockade response: the more, the better.
Zheng M
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101940
[TBL] [Abstract][Full Text] [Related]
11. Assessment of tumor mutation burden calculation from gene panel sequencing data.
Xu Z; Dai J; Wang D; Lu H; Dai H; Ye H; Gu J; Chen S; Huang B
Onco Targets Ther; 2019; 12():3401-3409. PubMed ID: 31123404
[No Abstract] [Full Text] [Related]
12. A novel tumor mutational burden estimation model as a predictive and prognostic biomarker in NSCLC patients.
Tian Y; Xu J; Chu Q; Duan J; Zhang J; Bai H; Yang Z; Fang W; Cai L; Wan R; Fei K; He J; Gao S; Zhang L; Wang Z; Wang J
BMC Med; 2020 Aug; 18(1):232. PubMed ID: 32843031
[TBL] [Abstract][Full Text] [Related]
13. Paired analysis of tumor mutation burden calculated by targeted deep sequencing panel and whole exome sequencing in non-small cell lung cancer.
Park S; Lee C; Ku BM; Kim M; Park WY; Kim NKD; Ahn MJ
BMB Rep; 2021 Jul; 54(7):386-391. PubMed ID: 34154699
[TBL] [Abstract][Full Text] [Related]
14. Analysis of tumor mutational burden and mutational landscape comparing whole-exome sequencing and comprehensive genomic profiling in patients with resectable early-stage non-small-cell lung cancer.
Choi SJ; Lee JB; Kim JH; Hong MH; Cho BC; Lim SM
Ther Adv Med Oncol; 2024; 16():17588359241240657. PubMed ID: 38523846
[TBL] [Abstract][Full Text] [Related]
15. Tumor mutational burden analysis of 2,000 Japanese cancer genomes using whole exome and targeted gene panel sequencing.
Hatakeyama K; Nagashima T; Urakami K; Ohshima K; Serizawa M; Ohnami S; Shimoda Y; Ohnami S; Maruyama K; Naruoka A; Akiyama Y; Kusuhara M; Mochizuki T; Yamaguchi K
Biomed Res; 2018; 39(3):159-167. PubMed ID: 29899191
[TBL] [Abstract][Full Text] [Related]
16. Genomic Profiles and Clinical Outcomes of Penile Squamous Cell Carcinoma With Elevated Tumor Mutational Burden.
Necchi A; Spiess PE; Costa de Padua T; Li R; Grivas P; Huang RSP; Lin DI; Danziger N; Ross JS; Jacob JM; Sager RA; Basnet A; Li G; Graf RP; Pavlick DC; Bratslavsky G
JAMA Netw Open; 2023 Dec; 6(12):e2348002. PubMed ID: 38150257
[TBL] [Abstract][Full Text] [Related]
17. Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity.
Hong TH; Cha H; Shim JH; Lee B; Chung J; Lee C; Kim NKD; Choi YL; Hwang S; Lee Y; Park S; Jung HA; Kim JY; Park YH; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH; Park WY
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33077514
[TBL] [Abstract][Full Text] [Related]
18. Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer.
Ricciuti B; Kravets S; Dahlberg SE; Umeton R; Albayrak A; Subegdjo SJ; Johnson BE; Nishino M; Sholl LM; Awad MM
J Immunother Cancer; 2019 Mar; 7(1):87. PubMed ID: 30922388
[TBL] [Abstract][Full Text] [Related]
19. Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence.
Klempner SJ; Fabrizio D; Bane S; Reinhart M; Peoples T; Ali SM; Sokol ES; Frampton G; Schrock AB; Anhorn R; Reddy P
Oncologist; 2020 Jan; 25(1):e147-e159. PubMed ID: 31578273
[TBL] [Abstract][Full Text] [Related]
20. Estimating tumor mutational burden across multiple cancer types using whole-exome sequencing.
Zhou C; Chen S; Xu F; Wei J; Zhou X; Wu Z; Zhao L; Liu J; Guo W
Ann Transl Med; 2021 Sep; 9(18):1437. PubMed ID: 34733989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]